可用於抑制巨噬細胞活化、抑制破骨細胞型成、抑制破骨細胞功能/或活化造骨細胞之含金線連糖苷之醫藥組合物及萃取液及其應用METHOD FOR INHIBITING ACTIVATION OF MACROPHAGES, INHIBITING FORMATION OF OSTEOCLASTS, INHIBITING FUNCTION OF OSTEOCLASTS, AND/OR ACTIVATING OSTEOBLASTS

專利類型

發明

專利國別 (專利申請國家)

美國

專利申請案號

12/454,001

專利證號

US 8,084,431 B2

專利獲證名稱

可用於抑制巨噬細胞活化、抑制破骨細胞型成、抑制破骨細胞功能/或活化造骨細胞之含金線連糖苷之醫藥組合物及萃取液及其應用METHOD FOR INHIBITING ACTIVATION OF MACROPHAGES, INHIBITING FORMATION OF OSTEOCLASTS, INHIBITING FUNCTION OF OSTEOCLASTS, AND/OR ACTIVATING OSTEOBLASTS

專利所屬機關 (申請機關)

中國醫藥大學

獲證日期

2011/12/27

技術說明

金線連糖苷(kinsenoside)是台灣金線連的主要成分，含量佔台灣金線連水萃取物約20 %。研究發現金線連糖苷能抑制巨噬細胞（macrophage）活化，可降低脂多糖在小鼠誘發的發炎反應。能抑制骨髓單核球分化成制破骨細胞（osteoclast），也能抑制破骨細胞蝕骨的功能，及或活化造骨細胞（osteoblast）產生礦化的功能。金線連糖苷能改善去卵巢小鼠誘發的股質疏鬆。金線連糖苷也能抑制第二型膠原蛋白誘發的小鼠關節炎。金線連糖苷具有抗骨質疏鬆、抗發炎、抗類風濕性關節炎的作用。可應用於台灣金線連改善骨質疏鬆健康食品的研發，及抗發炎等醫藥品的研發。 Kinsenoside is the major component of Anoectochilus formosanus, the content occupies aqueous extract of A. formosanus approximately 20%. Our study found that kinsenoside can suppress the macrophage activation, and it may reduce the inflammation induced by lipopolysaccharide in mic. Kinsenoside suppress the differentiation of bone marrow monocytes to osteoclast, which inhibits the resorption activity of osteoclast, and activates mineralization of ostoblast. Kinseoside ameliorates the ovariectomy-induced osteoporosis in mice. Kinsenoside can also suppress the type II collagen induced arthritis in mice. Thus, kinsenoside possessed activities of anti-osteoporosis, anti-inflammation, and anti-rheumatic arthritis. Therefore, kinsenoside may apply in the health food for anti-osteoporosis. It also may apply in the development of anti-inflammatory drug.

備註

本部(收文號1080024540)同意該校108年4月16日明產字第1080004951號函申請終止維護專利

連絡單位 (專責單位/部門名稱)

產學合作處生物科技發展育成中心

連絡電話

(04)2205-3366轉1581

網址